Add time:08/23/2019         Source:sciencedirect.com

A number of neurotoxic agents could potentially exert their action by degrading or modifying cytoskeleton components like neurofilaments (NF). Cytosine arabinoside (AraC) is an anticancer drug commonly used in leukemia treatment. Its side effects include neuronal cell death in the cerebellum and severe motor coordination deficits. We have previously shown that AraC administration (400 mg/kg bw) in adult rats reduced NF immunostaining in cerebellar neurons. To further delineate the susceptibility of individual NF isoforms (NF-H, NF-M, NF-L) to AraC, in the present study we used Western blot analysis to quantify their level. A significant and selective reduction of NF-H isoform was observed in the cerebellum of AraC-treated animals, compared to the controls. Administration of the antioxidant N-acetylcysteine (NAC) for a period of 14 days (prior to and during AraC treatment), which was previously shown to ameliorate the AraC-induced motor deficits in these animals, largely prevented the reduction in NF-H isoform. Given the significant role of NF proteins and particularly NF-H in maintaining structural integrity and synaptic transport, the observed loss of this isoform may be a key-target of AraC action in cerebellar neurons. Moreover, this study provides further data on the neuroprophylactic role of NAC in vivo against chemotherapy-induced toxicity.

We also recommend Trading Suppliers and Manufacturers of N(4)-chloroacetylcytosine arabinoside (cas 113737-52-3). Pls Click Website Link as below: cas 113737-52-3 suppliers